Tirzepatide

Mechanism of action

Tirzepatide is a 39-amino-acid synthetic peptide engineered as the first commercially successful dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The molecular design started from the native GIP sequence — chosen as the structural backbone because the native GLP-1 backbone proved less amenable to engineering high-affinity GIPR binding — with systematic substitutions to introduce GLP-1R cross-reactivity while preserving GIPR affinity. The result is a chimeric peptide that binds both receptors as a full or near-full agonist, with affinities approximately 5-fold higher at GIPR than at GLP-1R relative to the respective native ligands. Protease resistance and plasma half-life extension are achieved through two engineering features. The N-terminal His residue is followed by α-aminoisobutyric acid (Aib) at position 2, blocking DPP-4-mediated cleavage of the otherwise-vulnerable His-Ala bond. Lysine 20 carries a C20 fatty diacid moiety via a γ-glutamic acid and dual short polyethylene-glycol-like linkers, binding circulating serum albumin with high affinity and producing the ~5-day plasma half-life that supports once-weekly subcutaneous dosing. The pharmacological design parallels the engineering principles of semaglutide but applied to a chimeric backbone designed for dual receptor engagement. Mechanistically, tirzepatide engages two distinct β-cell signalling pathways. GLP-1R activation triggers Gαs/adenylate cyclase signalling — the same pathway engaged by semaglutide and other GLP-1R monoagonists. GIPR activation also signals through Gαs/cAMP but with distinct downstream effects on insulin granule pool dynamics and β-cell function. Combined receptor activation produces additive insulinotropic effect and additive effects on satiety, gastric emptying, and the broader metabolic phenotype. The dual-agonist pharmacology yields materially greater weight-loss efficacy than GLP-1R monoagonists at equivalent dose tiers — the principal clinical differentiator of tirzepatide established in the head-to-head SURPASS-2 trial against semaglutide. The mechanism of GIPR's contribution to the dual-agonist phenotype remains an active research question. In healthy subjects, GIP supports glucose-dependent insulin secretion but does not suppress glucagon and may stimulate it in hypoglycaemia. In type-2 diabetes, β-cell GIP responsiveness is reduced — the principal mechanism by which the incretin effect is attenuated in diabetes — leading to the historical assumption that GIPR pharmacology offered limited therapeutic potential. Tirzepatide's clinical success has reframed this: combined activation at both receptors restores incretin-effect responsiveness more completely than GLP-1R monoagonism, with additive effects on weight loss through mechanisms incompletely characterised but likely involving both central appetite circuits and direct adipose tissue effects through GIPR expression on adipocytes. Whether GIPR full agonism, biased agonism, or even functional antagonism contributes most to the clinical benefit remains debated; the empirical superiority of the dual-agonist over GLP-1R monoagonist is established. Downstream metabolic effects produce the tirzepatide clinical phenotype: 2-2.5% absolute HbA1c reduction in type-2 diabetes (larger than semaglutide), 15-22.5% body weight reduction depending on dose and duration (larger than semaglutide's 14.9% at the highest licensed Wegovy dose), favourable lipid and blood pressure changes, and emerging cardiovascular and renal outcome benefits being characterised in dedicated trials (SURPASS-CVOT for cardiovascular outcomes, SURMOUNT-MMO for MACE in obesity).

Tirzepatide 15 mg subcutaneous weekly produces 20.9% mean body weight loss over 72 weeks in non-diabetic adults with obesity (SURMOUNT-1, Jastreboff et al., NEJM 2022) — the largest pharmacological weight-loss effect documented in a peer-reviewed trial. The head-to-head SURMOUNT-5 trial subsequently confirmed superior weight-loss versus semaglutide 2.4 mg weekly at maximum licensed doses, cementing the dual-agonist mechanism's clinical advantage over GLP-1R monoagonism.

— Notable finding

Research history

Tirzepatide was developed by Eli Lilly through systematic medicinal chemistry programme exploring dual-agonist incretin pharmacology, with the molecular design originating from observations in the early-to-mid 2010s that chimeric peptides engaging both GIPR and GLP-1R might overcome the historical assumption of limited GIPR therapeutic potential. The development was based on the hypothesis — initially controversial — that combined incretin receptor activation could produce additive metabolic benefit beyond GLP-1R monoagonism. Phase II clinical development (2017-2018) showed dose-dependent HbA1c and weight-loss effects materially exceeding the contemporary GLP-1R monoagonist comparators, supporting Phase III development. The pivotal SURPASS programme (multiple Phase III trials, 2019-2022) established tirzepatide's superiority over placebo, GLP-1R agonist comparators (semaglutide, dulaglutide), and insulin comparators across the diabetes therapeutic spectrum. The head-to-head SURPASS-2 trial against semaglutide 1.0 mg weekly was particularly important — demonstrating that tirzepatide at all three licensed dose tiers (5, 10, 15 mg weekly) produced superior HbA1c and weight outcomes versus semaglutide at the time's standard dose. FDA approval for tirzepatide (Mounjaro) in type-2 diabetes came in May 2022. MHRA marketing authorisation in the UK followed in 2022. The Zepbound brand for obesity received FDA approval in November 2023 following the SURMOUNT-1 trial demonstrating 20.9% mean body weight loss over 72 weeks at the 15 mg/week dose in non-diabetic obese subjects. MHRA approval of Zepbound for chronic weight management in the UK followed. The SURMOUNT-5 head-to-head trial against semaglutide 2.4 mg weekly (Wegovy) — published 2024 — confirmed superior weight loss with tirzepatide 15 mg weekly versus semaglutide 2.4 mg weekly in non-diabetic obese subjects (~20% vs ~14% mean weight reduction), cementing tirzepatide as the higher-efficacy choice within the GLP-1-pathway class. The cardiovascular outcomes trial (SURPASS-CVOT) and renal outcomes trial are ongoing as of 2026. The commercial success of tirzepatide has paralleled and partly accelerated the broader 'GLP-1 weight loss' phenomenon of 2023-2026, with UK supply during 2023-2024 constrained similarly to semaglutide. NHS access through NICE technology appraisal pathways has expanded across 2025-2026 for both type-2 diabetes and obesity indications within specified eligibility criteria.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Tirzepatide has the second-largest clinical-trial safety dataset among incretin-pathway peptide drugs (semaglutide having the largest), accumulated through the SURPASS and SURMOUNT programmes spanning over 25,000 trial participants. The principal adverse events parallel the GLP-1R agonist class: gastrointestinal symptoms (nausea 15-30%, vomiting 5-15%, diarrhoea 10-20%, constipation 5-15%) are dose-dependent, most prominent during dose escalation, and account for the majority of treatment discontinuations. Dose-titration protocols (starting at 2.5 mg weekly, escalating to therapeutic doses over weeks-to-months) substantially mitigate the GI symptom burden. The glucose-dependent insulinotropic mechanism produces a favourable hypoglycaemia profile in monotherapy. Severe hypoglycaemia is rare when tirzepatide is used alone or with metformin; risk rises with concurrent sulphonylurea or insulin therapy, where dose reductions of the concurrent agents are recommended. The thyroid C-cell carcinoma class warning carried forward from earlier GLP-1R agonists is reflected in the FDA boxed warning and MHRA Summary of Product Characteristics contraindication for personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. The human clinical relevance of the rodent finding remains debated but the contraindication is maintained. Acute pancreatitis (uncommon, with absolute rates of ~0.5%) and acute biliary disease (cholecystitis, cholelithiasis — related to rapid weight loss) are documented in trial data and post-marketing surveillance. Modest heart rate elevation (~2-4 bpm) is consistent with the GLP-1R agonist class. Injection-site reactions are common but mild. Rare reports of diabetic retinopathy progression in pre-existing severe retinopathy have been documented. The dual GIPR/GLP-1R agonism has not produced safety signals distinct from those of GLP-1R monoagonists in the published trial data. Specifically, theoretical concerns about adipocyte GIPR effects driving adverse metabolic phenotypes have not been substantiated; the clinical phenotype is materially more beneficial than monoagonist comparators across HbA1c, weight, and lipid endpoints. Anti-tirzepatide antibodies develop in approximately 50% of treated patients but are generally non-neutralising and have not produced documented loss of efficacy. The SURPASS-CVOT cardiovascular outcomes trial is ongoing; class-level cardiovascular benefit observed with GLP-1R monoagonists provides a reasonable expectation of similar tirzepatide cardiovascular benefit, but this is not yet confirmed in dedicated outcome data.

UK regulatory status

Tirzepatide is fully MHRA-licensed in the United Kingdom across two indications. **Mounjaro** (tirzepatide 2.5, 5, 7.5, 10, 12.5, 15 mg subcutaneous weekly) is licensed for type-2 diabetes mellitus in adults. **Zepbound** (the same molecule under a separate brand name for the obesity indication) is licensed for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity. NHS prescription is supported by NICE technology appraisal guidance — TA924 for Mounjaro in type-2 diabetes (published 2023) and TA1026 for Zepbound in chronic weight management (published 2025). NHS supply of Zepbound through specialist obesity services is expanding across 2025-2026. Mounjaro is routinely prescribed in primary care within NICE-defined diabetes treatment pathways. Private prescription is widely available. Tirzepatide is a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012. Supply or possession for human use outside a valid prescription is regulated. There is no controlled-drug classification under the Misuse of Drugs Act 1971. As with semaglutide, unauthorised online supply of counterfeit tirzepatide has been a recurring MHRA enforcement concern; multiple MHRA warnings about counterfeit Mounjaro have been published. WADA does not classify tirzepatide as prohibited; it is not on the WADA Prohibited List as of 2026, consistent with the broader GLP-1R agonist class. Recreational athletic use raises distinct ethical and safety considerations but is not currently a doping violation.

Frequently asked questions